Everus Construction Group, Inc.
ECG
$94.91
-2.21%
Everus Construction Group, Inc. is a U.S. specialty contracting company operating through two segments — Electrical & Mechanical (E&M), which provides electrical, communications, fire suppression, and mechanical piping construction and maintenance services to public and private customers, and Transmission & Distribution (T&D), which serves electric and natural gas utilities plus transportation end markets in the West and Midwest. The company is a scaled, utility- and infrastructure-focused contractor with roughly 9,400 employees, positioned as a direct beneficiary of grid modernization, data center electrification, and utility capex cycles rather than a broad-based commercial builder. The investor narrative centers on the durability of that electrical/utility backlog and the company's ability to convert strong top-line growth into margin expansion, with recent results showing accelerating revenue and improving profitability. Debate now hinges on whether the stock's post-spinoff re-rating has run ahead of fundamentals, given a sharp multi-month drawdown despite continued double-digit growth and a consensus that remains firmly constructive.…
ECG
Everus Construction Group, Inc.
$94.91
People also watch
Quanta Services
PWR
Comfort Systems USA
FIX
EMCOR
EME
APi Group Corporation
APG
MasTec
MTZ
Investment Opinion: Should I buy ECG Today?
Rating: Buy (with high volatility). The core thesis is that ECG's 25.44% revenue growth, expanding margins, and fortress balance sheet are not reflected in a stock trading 28.7% above its 52-week low and 36% below its 52-week high, while the analyst consensus 'buy' rating and $176 average target imply 60.5% upside. The recent selloff appears to be a valuation and momentum reset rather than a fundamental break, given continued double-digit growth and a PEG of 0.54.
Supporting evidence: (1) trailing PE of 21.7x compresses to 17.4x forward, a 20% earnings growth implied by consensus EPS of $7.67 versus trailing $5.05; (2) revenue grew 25.44% YoY in Q1 2026 with sequential acceleration; (3) gross margin improved to 12.61% from 11.19%, and operating margin reached 7.49%; (4) TTM free cash flow of $229.6 million yields roughly 5.3% on the $4.37 billion market cap; and (5) the $176 average target implies 60.5% upside, with even the $152 low target implying 39% upside. The PEG of 0.54 and PS of 1.17x compare favorably to a sector where mid-teens PE multiples are typical.
Risks and conditions: the biggest risks are margin compression (gross margin of 12.61% is thin), a growth-stock de-rating (30–45% sector premium), and stale analyst targets (no recent news, wide $152–$200 range). This Buy would downgrade to Hold if gross margin falls below 11% or revenue growth decelerates below 15%, and to Sell if the stock breaks below the $100 handle with deteriorating fundamentals. Conversely, it would upgrade to Strong Buy if the stock reclaims $130 and forward EPS estimates rise above $8.00. Valuation verdict: fairly valued to modestly undervalued on a growth-adjusted basis (PEG 0.54), but at a premium to peers on trailing earnings; the stock is not cheap on absolute multiples but is attractive relative to its growth and cash flow.
Sign up to view all
ECG 12-Month Price Forecast
The forward view is bullish but with medium confidence, given the tension between strong fundamentals and a severe technical breakdown. Revenue growth of 25.44%, margin expansion, and a PEG of 0.54 support a valuation re-rating, while the 35.46% max drawdown and -20.39% three-month relative strength signal that the market is skeptical. The base case (50% probability) targets $130–$160, implying 19–46% upside, while the bull case (30%) reaches $176–$200 and the bear case (20%) risks $78–$100. I would upgrade to high confidence if the stock reclaims $130 with volume and gross margin holds above 12.5%; I would downgrade to neutral if revenue growth falls below 15% or gross margin drops below 11%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Everus Construction Group, Inc.'s 12-month outlook, with a consensus price target around $176.00 and implied upside of +85.4% versus the current price.
Average Target
$176.00
0 analysts
Implied Upside
+85.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$152 - $200
Analyst target range
Six analysts cover ECG with a consensus recommendation of "buy" (mean rating 1.57 on a 1–5 scale, where 1 is strong buy), and the average target price of $176.00 implies roughly 60.5% upside from the current $109.65 — an unusually wide gap that signals the sell-side views the recent selloff as overdone. The distribution skews bullish, with recent actions including Guggenheim upgrading to Buy from Neutral on April 30, 2026, and Stifel, Oppenheimer, and Freedom Broker maintaining Buy/Outperform ratings, while Cantor Fitzgerald and DA Davidson remain Neutral. Consensus estimates of $7.67 EPS and $6.36 billion revenue for the forward period underpin the constructive stance.
The target range of $152 to $200 is wide — a $48 spread, or roughly 44% of the current price — indicating high uncertainty and divergent assumptions. The $200 high target likely assumes continued 20%+ revenue growth, margin expansion toward 8–9% operating levels, and multiple re-rating back toward prior highs near $171, while the $152 low still implies about 39% upside and probably assumes slower growth or margin normalization rather than deterioration. Notably, even the lowest target sits well above the current price, suggesting analysts see the drawdown as a valuation disconnect rather than a fundamental break; however, the absence of recent downgrades alongside a 17.7% three-month decline raises the risk that targets are stale and could be revised lower if Q3 results disappoint.
Drowning in data?
Find the real signal!
Bulls vs Bears: ECG Investment Factors
The bull case rests on accelerating 25.4% revenue growth, expanding margins (gross margin up 142 bps YoY), a fortress balance sheet with 0.59 debt-to-equity, and a PEG of 0.54 that makes the 21.7x trailing PE look reasonable. The bear case is technical and valuation-driven: a 35.46% max drawdown, -20.39% three-month relative strength, and a 30–45% sector premium suggest the market is repricing growth expectations. On balance, the fundamental evidence is stronger than the technical evidence, but the single most important tension is whether the recent 17% slide reflects a temporary valuation disconnect or an early signal of slowing backlog conversion and margin pressure. Resolution likely comes at the next earnings report, where revenue growth and gross margin will determine whether the 60% analyst upside is realized or the targets are cut.
Bullish
- Revenue accelerating at 25% YoY: Q1 2026 revenue of $1.037 billion grew 25.44% year-over-year, extending a sequential climb from $921.5 million in Q2 2025 to $1.011 billion in Q4 2025. This acceleration on a $4 billion-plus annualized base is driven by the E&M segment ($430.3 million of segment revenue) and supports a durable utility/data-center electrification thesis.
- Margin expansion and operating leverage: Gross margin rose to 12.61% in Q1 2026 from 11.19% in Q1 2025, while operating margin reached 7.49% and EBITDA margin 8.55%. Net income of $58.3 million (5.62% net margin) and EPS of $1.14 show that 25% revenue growth is translating into disproportionate profit growth.
- Fortress balance sheet and strong FCF: Debt-to-equity is only 0.59, current ratio 1.76, and interest coverage 16.8x, with $293.4 million of cash. TTM free cash flow of $229.6 million (including $128.2 million in Q1 2026) yields roughly 5.3% on the $4.37 billion market cap, funding growth internally.
- Analyst targets imply 60% upside: Six analysts have a consensus 'buy' rating (mean 1.57) and an average target of $176.00, implying 60.5% upside from $109.65. Even the lowest target of $152 implies 39% upside, suggesting the sell-side views the recent 17.7% three-month decline as overdone.
Bearish
- Severe technical breakdown and relative weakness: The stock is down 17.70% over three months and 14.87% over six months versus S&P 500 gains of 2.69% and 7.48%, producing relative strength of -20.39% and -22.35%. It has fallen in seven of the last eight sessions to $109.65, near the bottom of its 52-week range ($78.14–$171.58), with a 35.46% max drawdown.
- Valuation premium versus sector: At 21.7x trailing earnings and 14.1x EV/EBITDA, ECG trades at a roughly 30–45% premium to the engineering & construction sector's mid-teens PE multiples. The 6.94x price-to-book is rich, leaving little room for execution missteps.
- Thin margins and project execution risk: Despite improvement, gross margin of 12.61% and operating margin of 7.49% remain thin for a contractor, leaving limited buffer against cost overruns or wage inflation. Any margin reversal would disproportionately hit earnings given the premium multiple.
- Stale analyst targets and no recent news: The $152–$200 target range is wide (44% of the current price) and no recent news or downgrades are captured, raising the risk that targets are stale. With a 4.89 short ratio and modest 1.11 million average volume, gap risk around earnings is elevated.
ECG Technical Analysis
ECG is in a corrective downtrend within a longer-term recovery: the stock is up 21.15% over the past year and 22.95% year-to-date, but the current price of $109.65 sits at roughly 34% of its 52-week range of $78.14 to $171.58 — far closer to the low than the high. That positioning reflects a stock that has surrendered most of its momentum gains and is now testing the lower third of its annual range, a zone that historically attracts value buyers but also carries falling-knife risk if the trend persists. The 35.46% max drawdown confirms this has been a meaningful de-rating rather than a minor pullback.
Short-term momentum is clearly negative and diverging from the longer-term uptrend: the stock is down 1.46% over one month, 17.70% over three months, and 14.87% over six months, while the S&P 500 is up 1.22%, 2.69%, and 7.48% over the same windows. Relative strength tells the story — -20.39% versus SPY over three months and -22.35% over six months, even though the one-year relative strength remains positive at +5.62%. The recent sequence is particularly weak: after a rally to $132.74 on October 6, the stock has fallen in seven of the last eight sessions to $109.65, a roughly 17% slide in under two weeks, suggesting distribution and momentum breakdown rather than orderly consolidation.
Key technical levels are well defined: support sits at the 52-week low of $78.14, with an intermediate shelf around $109–$112 that is being tested right now, while resistance is the 52-week high of $171.58 and, more immediately, the $130–$135 area where the October rally failed. A decisive break below $109 would open the door to a retest of the $100 handle and potentially the annual low, whereas reclaiming $130 would signal the correction has bottomed. With a beta not provided but a 35.46% max drawdown and a 4.89 short ratio indicating nearly five days of average volume held short, volatility is elevated and position sizing should account for wide $20+ swings; the 1.11 million average volume is modest for a $4.4–6.3 billion market cap, amplifying gap risk around earnings.
Beta
—
—
Max Drawdown
-43.9%
Largest decline past year
52-Week Range
$78-$172
Price range past year
Annual Return
+8.5%
Cumulative gain past year
| Period | ECG Return | S&P 500 |
|---|---|---|
| 1m | -17.5% | -1.0% |
| 3m | -27.0% | +2.9% |
| 6m | -30.2% | +6.5% |
| 1y | +8.5% | +13.1% |
| ytd | +6.4% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ECG Fundamental Analysis
Revenue is growing robustly and, importantly, accelerating: Q1 2026 revenue of $1.037 billion rose 25.44% year-over-year versus $826.6 million in Q1 2025, extending a streak that has climbed sequentially from $921.5 million in Q2 2025 and $986.8 million in Q3 2025 to $1.011 billion in Q4 2025. The E&M segment is the dominant driver at $430.3 million of reported segment revenue versus $104.3 million for T&D, meaning the electrical/mechanical contracting business carries the growth story. This trajectory — roughly 25% growth on a $4 billion-plus annualized base — supports a constructive investment case built on utility and data-center-driven electrical demand rather than cyclical commercial construction.
Profitability is solid and improving: Q1 2026 net income was $58.3 million (5.62% net margin) on gross profit of $130.7 million, a 12.61% gross margin, up from 11.19% in Q1 2025 and 11.62% in Q4 2025. Operating income of $77.7 million produced a 7.49% operating margin, and EBITDA of $88.6 million equates to an 8.55% EBITDA margin — healthy for a specialty contractor where low-to-mid single-digit operating margins are typical. The company is clearly profitable with EPS of $1.14 in the latest quarter, and the margin expansion alongside 25% revenue growth suggests operating leverage and favorable project mix rather than margin-dilutive volume chasing.
Balance sheet and cash flow are strong: debt-to-equity is just 0.59, the current ratio is 1.76, and interest coverage is a comfortable 16.8x, while ROE of 32.0% and ROA of 11.7% are excellent for the industry. Free cash flow is robust — $229.6 million TTM and $128.2 million in Q1 2026 alone against $15.5 million of capex — giving an FCF yield of roughly 5.3% on the $4.37 billion market cap, and cash stood at $293.4 million at quarter-end. The company funds growth internally with minimal external financing needs, and the 0.59 debt-to-equity ratio leaves ample capacity for acquisitions or buybacks, though the absence of a dividend (0% yield, 0% payout) means all returns are reinvested or retained.
Quarterly Revenue
$1.0B
2026-03
Revenue YoY Growth
+25.4%
YoY Comparison
Gross Margin
12.6%
Latest Quarter
Free Cash Flow
$229625000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ECG Overvalued?
Because net income is positive ($58.3 million in Q1 2026), the PE ratio is the appropriate primary metric: the trailing PE is 21.7x versus a forward PE of 17.4x, a roughly 20% compression that implies the market expects meaningful earnings growth — consistent with consensus EPS of $7.67 versus trailing EPS of about $5.05. The PEG ratio of 0.54 is notably low, suggesting the stock is inexpensive relative to its growth rate, while the PS ratio of 1.17x and EV/Sales of 1.39x are modest for a company growing revenue 25%.
On peer comparison, the stock trades at 21.7x trailing earnings and 14.1x EV/EBITDA against an engineering & construction sector where mid-teens PE multiples are more typical, implying a premium of roughly 30–45% on trailing earnings — but that premium is arguably justified by 25% revenue growth, 32% ROE, and 12.6% gross margins that exceed typical contractor economics. The 6.94x price-to-book is rich versus the sector, reflecting an asset-light, high-return business model, while the 27.8x price-to-cash-flow and 1.17x PS are less demanding. On balance, the valuation is not stretched on growth-adjusted terms (PEG 0.54) but does embed expectations of continued execution.
Historically, the stock's PE has ranged from about 12.9x (Q1 2025) to 25.9x (Q1 2026), and the current 21.7x sits in the upper-middle of that band — below the 25.9x peak but well above the 12.9x trough. The PS ratio of 1.17x is dramatically below the 5.82x recorded in Q1 2026 historical data, though that figure reflects a different share-count/market-cap basis and should be treated cautiously; the more reliable read is that the stock has de-rated from its post-spinoff highs. At 21.7x trailing and 17.4x forward, the market is pricing in optimistic-but-not-euphoric growth, leaving room for multiple support if earnings delivery continues.
PE
21.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 13x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on thin contractor margins and execution. Gross margin of 12.61% and operating margin of 7.49% leave little cushion; a 100 bp gross margin decline would cut pre-tax income by roughly 8% given Q1 2026 gross profit of $130.7 million. Revenue is concentrated in the E&M segment ($430.3 million of segment revenue versus $104.3 million for T&D), so a slowdown in electrical/mechanical project awards would disproportionately hit results. Interest coverage of 16.8x and debt-to-equity of 0.59 are comfortable, but the absence of a dividend (0% yield) means no income buffer, and the company depends on continued 25% growth to justify its premium multiple.
Market and competitive risks include valuation compression and relative underperformance. At 21.7x trailing and 17.4x forward earnings, ECG trades at a 30–45% premium to sector mid-teens PE multiples; a de-rating to 15x forward EPS of $7.67 would imply a price near $115, roughly flat to current levels, while a de-rating to 13x would imply about $100. The stock's beta is not provided, but its 35.46% max drawdown and -20.39% three-month relative strength versus the S&P 500 indicate high sensitivity to growth-stock rotation. With no recent news captured, the risk of stale analyst targets ($152–$200 range) and potential downgrades is material, and the 4.89 short ratio signals persistent bearish positioning.
Worst-case scenario: a combination of slowing utility capex, margin compression from project cost overruns, and a growth-stock de-rating could drive the stock toward its 52-week low of $78.14, a decline of approximately 28.7% from $109.65. If analyst targets are revised down to the low end and the multiple compresses to the historical trough of 12.9x on forward EPS of $7.67, the implied price is about $99, a 9.7% decline; a more severe scenario applying 12.9x to a reduced EPS estimate of $6.50 would imply roughly $84, near the 52-week low. Investors could lose 25–30% in this adverse scenario, with gap risk amplified by modest 1.11 million average volume.
FAQ
The most severe risk is margin compression: gross margin of 12.61% and operating margin of 7.49% are thin, and a 100 bp decline would cut pre-tax income by roughly 8%. Second is valuation de-rating: at 21.7x trailing earnings and a 30–45% sector premium, a rotation away from growth stocks could compress the multiple toward 13x, implying a price near $100. Third is revenue concentration in the E&M segment ($430.3 million versus $104.3 million for T&D), making results vulnerable to a slowdown in electrical/mechanical project awards. Fourth is technical and liquidity risk: the 35.46% max drawdown, 4.89 short ratio, and modest 1.11 million average volume amplify gap risk around earnings.
The 12-month forecast has three scenarios: a base case (50% probability) targeting $130–$160 on 15–20% revenue growth and stable margins; a bull case (30%) targeting $176–$200 on continued 20%+ growth and multiple re-rating; and a bear case (20%) targeting $78–$100 on margin compression and growth deceleration. The base case is most likely, assuming forward EPS near the $7.67 consensus and no major deterioration in utility capex. The key assumption is that gross margin holds above 11.5% and revenue growth stays above 15%, which would support a partial recovery toward the $130–$160 range.
ECG trades at 21.7x trailing earnings and 17.4x forward earnings, a roughly 30–45% premium to the engineering & construction sector's mid-teens PE multiples. However, the PEG ratio of 0.54 and PS of 1.17x suggest the premium is justified by 25.44% revenue growth and 32.0% ROE. The stock has de-rated from its post-spinoff highs, with the PE sitting in the upper-middle of its 12.9x–25.9x historical range. On a growth-adjusted basis, the stock looks modestly undervalued, but on absolute multiples it is fairly valued to slightly rich, implying the market expects continued execution rather than euphoria.
From a risk/reward perspective, ECG offers 60.5% upside to the $176 average analyst target against roughly 28.7% downside to the $78.14 52-week low, a favorable ratio of about 2:1. The stock trades at 17.4x forward earnings with a PEG of 0.54, and revenue is growing 25.44% with expanding margins, supporting the bullish case. However, the 35.46% max drawdown and -20.39% three-month relative strength indicate high volatility and momentum risk, and the 4.89 short ratio signals persistent bearish positioning. It is a good buy for growth-oriented investors with a medium-to-long horizon who can tolerate wide $20+ swings, but conservative investors may prefer to wait for a reclaim of $130 or a confirmed bottom above $109.
ECG is better suited for medium-to-long-term holding (minimum 12–18 months) given its growth stage, 25.44% revenue growth, and the time needed for utility and data-center electrification contracts to convert into earnings. The stock's high volatility — 35.46% max drawdown and wide $20+ swings — makes it unsuitable for short-term trading unless using tight risk controls. The 0% dividend yield means no income support, so returns depend entirely on capital appreciation and multiple re-rating. A suggested minimum holding period of 12 months allows for at least four earnings reports to validate the growth and margin trajectory.